Showing results (21-30 of 163) with videos related to
Sort By:
Pageof 17
Cancer Chemotherapy and Pharmacology|March 5, 2016
Predicting survival of pancreatic cancer patients treated with gemcitabine using longitudinal tumour size dataThierry Wendling, Hitesh Mistry, Kayode Ogungbenro, et al.Journal of Pharmacokinetics and Pharmacodynamics|January 9, 2009
Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 1: comparison of uniresponse and multiresponse designs using PopDesMarylore Chenel, François Bouzom, Leon Aarons, et al.British Journal of Clinical Pharmacology|October 19, 2020
Dose individualisation in oncology using chemotherapy-induced neutropenia: Example of docetaxel in non-small cell lung cancer patientsAurélie Lombard, Hitesh Mistry, Leon Aarons, et al.Computer Methods and Programs in Biomedicine|September 6, 2005
The use of a modified Fedorov exchange algorithm to optimise sampling times for population pharmacokinetic experimentsKayode Ogungbenro, Gordon Graham, Ivelina Gueorguieva, et al.Journal of Biopharmaceutical Statistics|March 11, 2008
Incorporating correlation in interindividual variability for the optimal design of multiresponse pharmacokinetic experimentsKayode Ogungbenro, Gordon Graham, Ivelina Gueorguieva, et al.Journal of Pharmacokinetics and Pharmacodynamics|February 8, 2007
Optimal design for multiresponse pharmacokinetic-pharmacodynamic models - dealing with unbalanced designsKayode Ogungbenro, Ivelina Gueorguieva, Oneeb Majid, et al.Computer Methods and Programs in Biomedicine|February 13, 2007
A program for individual and population optimal design for univariate and multivariate response pharmacokinetic-pharmacodynamic modelsIvelina Gueorguieva, Kayode Ogungbenro, Gordon Graham, et al.CPT: Pharmacometrics & Systems Pharmacology|January 17, 2023
A "middle-out approach" for the prediction of human drug disposition from preclinical data using simplified physiologically based pharmacokinetic (PBPK) modelsEstelle Yau, Michael Gertz, Kayode Ogungbenro, et al.British Journal of Clinical Pharmacology|July 17, 2021
Evaluation of area under the concentration curve adjusted by the terminal-phase as a metric to reduce the impact of variability in bioequivalence testingAdam J Lucas, Kayode Ogungbenro, Shuying Yang, et al.The Journal of Pharmacy and Pharmacology|June 28, 2017
Choosing an optimal input for an intravenous glucose tolerance test to aid parameter identificationEmma C Martin, James W T Yates, Kayode Ogungbenro, et al.Pageof 17